Pexion

RSS

imepitoin

Authorised
This medicine is authorised for use in the European Union.

Overview

An overview of Pexion and why it is authorised in the EU

Pexion is a veterinary medicine used in dogs to:

  • reduce the frequency of generalised seizures (fits affecting most or all of the brain) due to epilepsy of unknown causes (idiopathic). It should be used after careful evaluation of alternative treatment options;
  • reduce anxiety and fear associated with noise phobia.

Pexion contains the active substance imepitoin

This EPAR was last updated on 15/08/2018

Authorisation details

Product details
Name
Pexion
Agency product number
EMEA/V/C/002543
Active substance
imepitoin
International non-proprietary name (INN) or common name
imepitoin
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QN03AX90
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Revision
6
Date of issue of marketing authorisation valid throughout the European Union
25/02/2013
Contact address

Binger Strasse 73
55216 Ingelheim/Rhein
Germany

Product information

05/07/2018 Pexion - EMEA/V/C/002543 - II/0011/G

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Other antiepileptics
  • Antiepileptics

Therapeutic indication

For the reduction of the frequency of generalised seizures due to idiopathic epilepsy in dogs for use after careful evaluation of alternative treatment options.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings
1 rating